Primavera Capital Group led a $81m Series C round in ZAP Surgical.

Primavera Capital Group led a $81m Series C round in ZAP Surgical, a medical technology company developing a next-generation radiosurgical robot for non-invasive tumor ablation, with participation from GT Healthcare Capital Partners, Chow Tai Fook Enterprises, ShangBay Capital, and Hogy Medical, who joined existing investors Foxconn Technology Group and Varian Medical Systems. "Although over the past 3 decades stereotactic radiosurgery has become a well-established non-invasive tool for treating a broad array of human pathologies, globally more than 2m people who suffer from brain, head & neck cancer annually go untreated. ZAP Surgical welcomes this group of world-class investors in our now common quest to transform the lives, and very often cure, millions of patients each year by means of the ZAP-X surgical robot," John R. Adler, ZAP Surgical Systems CEO.